Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
Date:11/9/2009

edically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to complete cost-effective clinical trials or meet the projected development timelines for the drug candidates in our
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
3. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
4. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
5. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
6. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... At the American Association of Neurological Surgeons (AANS) Annual ... , Elekta will highlight Leksell Gamma Knife® Registry ... enormous amount of data – generated by thousands of ... advance clinical research and further optimize patient care. ... allows practitioners to store, retrieve, and analyze Gamma Knife ...
(Date:5/1/2015)... , May 1, 2015 ... expanded its current therapeutic focus beyond addiction ... serious psychiatric disorders. Braeburn has acquired an ... second-generation) antipsychotic risperidone for treatment of schizophrenia ... Braeburn acquires global rights to other potential ...
(Date:5/1/2015)... May 1, 2015  Legendary actor and director ... new PBAFacts campaign designed to educate and encourage patients ... about Pseudobulbar Affect (PBA) and to speak with their ... actor has the ability to cry and laugh on ... control experienced by people living with PBA episodes. ...
Breaking Medicine Technology:Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 2Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 2Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 3
... and NEW YORK, Nov. 9, 2010 ... ACCP ), a biopharmaceutical company leveraging its proprietary drug-delivery ... care and diabetes, announced today that its Chairman, Steven Rouhandeh, ... Investors Conference on Friday, November 12, 2010, at 1:00 pm ...
... Nov. 9, 2010 MonoSol Rx, the ... delivery company specializing in proprietary pharmaceutical film products, today ... 7,824,588 from the United States Patent and Trademark Office ... intellectual property protection for the Company,s film products and ...
Cached Medicine Technology:Access Pharmaceuticals to Present at LifeTech Capital Miami Medical Investors Conference on November 12th 2MonoSol Rx Issued Strategic U.S. Patent Governing the Manufacturing of Pharmaceutical Films 2MonoSol Rx Issued Strategic U.S. Patent Governing the Manufacturing of Pharmaceutical Films 3
(Date:5/4/2015)... Louis, Missouri (PRWEB) May 04, 2015 ... recognized as the “Gateway to the West,” so it ... “Gateway for Veterans Program”, says Dr. Ben Litalien, Chief ... International Franchise Association’s VetFran program and will provide veterans ... , Zerorez® is proud to have a number ...
(Date:5/3/2015)... Michigan (PRWEB) May 03, 2015 ... on their Facebook page. , Their Facebook ... the many services the Practice has, it’s multiple locations, ... , Women’s Excellence has a very strong social media ... Instagram and You Tube. , Women’s Excellence is ...
(Date:5/3/2015)... “ BolehVPN ” was featured on NewsWatch as part of ... technology products available to consumers. Scott Steinberg, a technology expert ... with viewers how to protect their private information. , A ... and even more so online. It helps everyone stay connected ... world. In terms of work, the internet makes things more ...
(Date:5/3/2015)... 03, 2015 HealthPostures, a pioneering ... announces its appearance at the , May 5 - ... HealthPostures will exhibit at the conference include its bestselling ... stand solutions is the 6100 TaskMate Executive. Features of ... an adjustable keyboard tray, extended platform work surface and ...
(Date:5/2/2015)... Viejo, CA (PRWEB) May 02, 2015 ProText ... exclusively for use in Final Cut Pro X. ProText ... for use in Final Cut Pro X . ... single keyframe with Pixel Film Studios' ProText Kinetic 2. , ... Start by staggering two ProText Kinetic presets in the ...
Breaking Medicine News(10 mins):Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2
... News) -- More than half of U.S. jails didn,t receive ... H1N1 swine flu, a new study says. Jail and ... diseases. The steady stream of new arrivals can introduce new ... it easy for diseases to spread, researchers from the U.S. ...
... have been linked to depression, according to UT Southwestern ... Study. It is believed to be the largest such ... already are associated with a cavalcade of health woes ... published in Mayo Clinic Proceedings ...
... , THURSDAY, Jan. 5 (HealthDay News) -- Toddlers who miss ... later in life, a new study indicates. Researchers looked ... that depriving them of a single daily nap resulted in ... problem-solving abilities. "Many young children today are not getting ...
... clinical trial found that rilonacept, an inhibitor of ... flares that occur when initiating uric acid-lowering therapy. ... IL-1 targeted therapy in prevention of gout flaresshow ... serious infections or treatment-related serious adverse events reported. ...
... vector-borne disease in the United States, with the majority of ... since the agent of the disease, the spirochete Borrelia ... However, the number of Lyme disease cases have steadily increased. ... of the Journal of Medical Entomology called "What ...
... Reporter , WEDNESDAY, Jan. 4 (HealthDay News) -- A vaccine ... severe liver damage and even liver cancer, might be possible ... , There is currently no vaccine for hepatitis C, which ... HIV, the hepatitis C virus mutates easily and has always ...
Cached Medicine News:Health News:Many Jails Got No Flu Shots During H1N1 Outbreak: CDC 2Health News:Low vitamin D levels linked to depression, UT Southwestern psychiatrists report 2Health News:Missed Naps Could Put Toddlers at Risk for Mood Disorders 2Health News:Clinical trial demonstrates that rilonacept significantly reduces gout flares 2Health News:Clinical trial demonstrates that rilonacept significantly reduces gout flares 3Health News:How can Lyme disease be prevented and controlled? 2Health News:Novel Hepatitis C Vaccine Shows Some Early Promise 2Health News:Novel Hepatitis C Vaccine Shows Some Early Promise 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: